NCT06308588View on ClinicalTrials.gov

Phase I/II Study of the Combination of Blinatumomab and Asciminib in Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

40

Participants

Timeline

Start Date

August 5, 2024

Primary Completion Date

May 1, 2027

Study Completion Date

May 1, 2029

Conditions

Philadelphia Chromosome-PositiveAcute Lymphoblastic Leukemia

Interventions

DRUG

Blinatumomab

Given by Infusion

DRUG

Asciminib

Given by PO

Trial Locations (1)

77030

RECRUITING

MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

Novartis Pharmaceuticals

All Listed Sponsors

collaborator

Novartis Pharmaceuticals

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER